Ian Churcher

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Tau therapeutic strategies for the treatment of Alzheimer's disease
    Ian Churcher
    Department of Discovery Research, GlaxoSmithKline Medicines Research Centre, Stevenage, Herts SG1 2NY, UK
    Curr Top Med Chem 6:579-95. 2006
  2. ncbi request reprint Small-molecule modulation of cellular chaperones to treat protein misfolding disorders
    Lisa A Sloan
    Department of Discovery Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
    Curr Opin Drug Discov Devel 12:666-81. 2009
  3. ncbi request reprint gamma-Secretase as a target for drug intervention in Alzheimer's disease
    Timothy Harrison
    Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow Essex CM20 2QR, UK
    Curr Opin Drug Discov Devel 7:709-19. 2004
  4. ncbi request reprint Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease
    Ian Churcher
    Department of Medicinal Chemistry, Merck Sharp and Dohme, The Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK
    Curr Pharm Des 11:3363-82. 2005
  5. ncbi request reprint The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse
    Jonathan D Best
    Department of In Vivo Neuroscience, Merck Sharp and Dohme, Neurosciene Research Centre, Harlow, UK
    J Pharmacol Exp Ther 320:552-8. 2007

Collaborators

  • Lisa A Sloan
  • John R Atack
  • D Beher
  • Timothy Harrison
  • Jonathan D Best
  • Huw D Lewis
  • Semantha Ellis
  • Michael A Reilly
  • Christine Boussiquet-Leroux
  • Ruth O'Donnell
  • Neil Wilkie
  • Mark S Shearman
  • Philippe A Laroque
  • Thomas W Rosahl
  • David W Smith

Detail Information

Publications5

  1. ncbi request reprint Tau therapeutic strategies for the treatment of Alzheimer's disease
    Ian Churcher
    Department of Discovery Research, GlaxoSmithKline Medicines Research Centre, Stevenage, Herts SG1 2NY, UK
    Curr Top Med Chem 6:579-95. 2006
    ..This review will describe the tau-related etiology of Alzheimer's disease and other tauopathies as well as the therapeutic strategies to inhibit the hyperphosphorylation of tau...
  2. ncbi request reprint Small-molecule modulation of cellular chaperones to treat protein misfolding disorders
    Lisa A Sloan
    Department of Discovery Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
    Curr Opin Drug Discov Devel 12:666-81. 2009
    ....
  3. ncbi request reprint gamma-Secretase as a target for drug intervention in Alzheimer's disease
    Timothy Harrison
    Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Harlow Essex CM20 2QR, UK
    Curr Opin Drug Discov Devel 7:709-19. 2004
    ..In this review, progress in the development of small-molecule inhibitors will be described, and potential toxicity issues associated with the development of gamma-secretase inhibitors discussed...
  4. ncbi request reprint Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease
    Ian Churcher
    Department of Medicinal Chemistry, Merck Sharp and Dohme, The Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK
    Curr Pharm Des 11:3363-82. 2005
    ..In this review we describe the literature regarding the discovery of the nature of gamma-secretase, the development of small molecule inhibitors and their in vivo profiles...
  5. ncbi request reprint The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse
    Jonathan D Best
    Department of In Vivo Neuroscience, Merck Sharp and Dohme, Neurosciene Research Centre, Harlow, UK
    J Pharmacol Exp Ther 320:552-8. 2007
    ..An understanding of the mechanisms whereby MRK-560 shows differentiation between the APP and Notch proteolytic pathway of gamma-secretase should provide the basis for the next generation of gamma-secretase inhibitors...